FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:213-215 July 13, 2006 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Mutations in the epidermal growth factor receptor gene (EGFR) occur in 10 to 20 percent of non–small-cell lung cancers, specifically adenocarcinomas, and are associated with the response to EGFR tyrosine kinase inhibitors (erlotinib and gefitinib).¹ However, the results of screening of small-cell lung cancers for EGFR mutations have been negative.² Thus, small-cell lung cancers are not routinely tested for EGFR mutations, nor have they been systematically evaluated for responsiveness to EGFR tyrosine kinase inhibitors.

A 45-year-old woman who had never smoked and who had masses in the right lung, pleura, mediastinum, and frontal lobe was . . . [Full Text of this Article]

This article has been cited by other articles:

• Tatematsu, A., Shimizu, J., Murakami, Y., Horio, Y., Nakamura, S., Hida, T., Mitsudomi, T., Yatabe, Y. (2008). Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer. Clin. Cancer Res. 14: 6092-6096 [Abstract] [Full Text]